Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label SAR445088 safety study in adults with cold agglutinin disease
NL-OMON54300Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of riliprubart, sponsored by Sanofi. Started Aug 2021; status: recruiting.
02
Drugs
riliprubart
Beyond the preview
Go deeper on NL-OMON54300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54300.